Autopsy report · NCT03489265

Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence

“Difficult to recruit severely affected patients with fecal incontinence”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of North Carolina, Chapel Hill

Sponsor type

University, hospital or other

Conditions

Fecal Incontinence; Accidental Bowel Leakage; Anal Incontinence; Diarrhea; Urge Incontinence

Interventions

Eluxadoline 100 mg; Placebo

Participants

0

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.